METHOD FOR DETERMINING CLINICAL EFFECTIVENESS IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA Russian patent published in 2015 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention can be used for monitoring the clinical antitumour effectiveness in patients suffering B-cell chronic lymphocytic leukaemia. For this purpose, CD20-positive B-cells are measured in the peripheral blood after a therapeutic course. That is combined with determining a mean activity of CB20 antigen fluorescence on B-lymphocytes, as well as the CD25-positive B-cell count. If the measured CD20-positive B-cell count falls within the range of 0 to 20%, while the CD25-positive B-cell count is from 0 to 20% with the mean CB20 antigen fluorescence intensity of 150 standard units or more, the treatment appears to be effective. The CD20-positive B-cell and CD25-positive B-cell counts exceeding 20% with the mean CB20 antigen fluorescence intensity of less than 150 standard unit show the non-effective treatment.

EFFECT: using the given method enables stating the efficacy of the conduced therapeutic regimens at the earlier stages of the disease, before any clinical manifestations that offers a clinician the possibility to correct the therapeutic approach in good time, and reduces the rate of potential complications of using the new preparations.

3 ex, 6 dwg